WHO vaccine-preventable diseases: monitoring system. 2014 global summary

Last updated 15-Jul-2014 (Data received as of 8-Jul-2014)
Next overall update Fall 2014
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 5'7801 Infant (under 12 months) mortality rate: 152
GDP / capita (US$): 15'5861 Child (under 5 years) mortality rate: 182

Population data in thousands3

  2013  2012  2011  2010  2009  2000  1990  1980 
Total population 77'447  76'424  75'424  74'462  73'543  65'911  56'362  38'890 
Births 1'455  1'454  1'445  1'427  1'401  1'228  1'839  1'748 
Surviving infants 1'433  1'431  1'420  1'401  1'375  1'191  1'751  1'604 
Pop. less than 5 years 7'090  7'003  6'833  6'556  6'339  6'317  9'313  6'927 
Pop. less than 15 years 18'440  18'120  17'834  17'586  17'489  22'850  25'543  16'988 
Female 15-49 years 22'950  22'832  22'682  22'507  22'268  17'571  12'228  8'518 

Number of reported case

(Click for retrospective incidence data for Iran (Islamic Republic of))
Diphtheria 190  150  132  106  58  18  373  139 
Japanese encephalitis
Measles 189  332  73  538  262  11'874  5'341  31'130 
Mumps 10'417 
Pertussis 1'415  1'329  650  464  590  94  1'230  20'395 
Polio* 15  80 
Rubella 32  30  20  24  11  1'154 
Rubella (CRS) 49 
Tetanus (neonatal) 13  26 
Tetanus (total) 10  13  18  14  27  30  86 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Iran (Islamic Republic of))
Vaccine year result method % card seen                                                
BCG 1989  92  EPI     100  100  99  99  99  99  95 
DTP1 1986  94  EPI     98  98  99  99  99  100 
DTP3 1989  88  EPI     98  99  99  99  99  100  91  32 
HepB_BD          99  96  99  99  99  99 
HepB3          99  98  99  99  99  100 
Hib3         
JapEnc         
MCV 1996  96  MICS   98  98  98  99  99  99  100  85  39 
MCV2          97  97  99  99  99  100 
PCV1         
PCV3         
Pol3 1989  88  EPI     98  99  99  99  99  100  90  38 
Rota1         
Rota_last         
Rubella1          98  98  99  99 
TT2plus          25  95  20  22  30  46  63 
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Iran (Islamic Republic of))
BCG 99  99  99  99  99  99  95 
DTP1 98  99  99  99  99  99  97  57 
DTP3 98  99  99  99  99  99  91  32 
HepB3 99  98  99  99  99  99 
HepB_BD 99  96  99  99  99  99 
Hib3
MCV 98  98  99  99  99  99  85  39 
MCV2 97  97  99  99  99  99 
PAB 95  95  95  95  83  82  71 
PCV3
Pol3 98  99  99  99  99  99  90  38 
Rota_last

Number of districts in the country 411  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2013 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DT 2, 4, 6, 18 months; 6 years; Yes
DTwP 2, 4, 6, 18 months; 6 years; Yes
HepB birth; 2, 6 months; Yes also specified high risk group, HCWs, Medical students
Influenza > 65 years; Yes pregnant women, healthcare workers and persons with chronic disease
MMR 12, 18 months; Yes
Measles Yes Measles outbreak response
MenAC Yes military
OPV birth; 2, 4, 6, 18 months; 6 years; Yes
Td Yes repeated every 10 years - military and pregnant women
Varicella Yes Children with lymphatic and hematologic malignancies and their siblings
YF Yes travelers

Immunizaton indicators

Indicator Expected answer 2013  2012  2011  2010  2009  2008  2007 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2012-2016  2012-2016  2012-2016  2010-2014  2010-2014  2005-2009  2005-2009 
Nº of districts with microplans that include activities to raise immunization coverage number 10 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes       

System performance

Total Nº districts in country number 411  405  392  360  356  348  348 
Nº districts with DTP3 coverage >=80% number 411  405  392  360  356  348 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number 410  405  387  355  347  339   
% of districts with MCV1 coverage >=95% From 0 to 100% 100  100  99  99  97  97   

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes       
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Estimated percentage of routine vaccines funded by Government From 0 to 100% 100  100  100  100  100  100  100 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.